A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2002
10/23/2002	CN1093127C 哌嗪衍生物 Piperazine derivatives
10/23/2002	CN1093124C Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma
10/23/2002	CN1092985C Kelp product and its making method and use
10/23/2002	CN1092968C Pharmaceuticals for treating outer skin blood vessel disease in cold seasons
10/22/2002	US6469174 Substituted pyrrolobenzimidazoles for treating inflammatory diseases
10/22/2002	US6469056 Pharmaceutically active compounds, their preparation and use as ECE-inhibitors
10/22/2002	US6469055 Modulating expression, production, or formation of amyloid precursor protein by administering a nonsteroidal antiinflammatory agent that is a cyclooxygenase inhibitor
10/22/2002	US6469054 Aryl sulphonamides and analogues
10/22/2002	US6469053 Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response
10/22/2002	US6469045 Thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products; oral administration
10/22/2002	US6469036 Peptidyl heterocyclic ketones useful as tryptase inhibitors
10/22/2002	US6469032 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
10/22/2002	US6469029 Azacycloalkanone serine protease inhibitors
10/22/2002	US6469027 N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
10/22/2002	US6469024 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
10/22/2002	US6469018 Compounds
10/22/2002	US6469016 Treatment of female sexual dysfunction using phosphodiesterase inhibitors
10/22/2002	US6469011 Benzenesulfonamide compounds useful as TXA2 and 5-HT2 receptor antagonists
10/22/2002	US6469007 P-substituted-n-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl) -piperazin-1-yl)-propyl)-n-pyridin-2-yl-benzamide,
10/22/2002	US6469004 Benzoheterocycles and their uses as MEK inhibitors
10/22/2002	US6468998 Pyrrolidine compounds and medicinal utilization thereof
10/22/2002	US6468986 Composition comprising polynucleotide and polycationic agent which exhibits net positive electrical charge at physiological ph, and is capable of mediating entry of polynucleotides into cell
10/22/2002	US6468974 Oligopeptides that provide desirable in vitro and in vivo growth hormone releasing activity and have at least one other desirable biological activity such as increased retention time
10/22/2002	US6468960 Therapeutic compositions and methods for enhancing angiogenesis
10/22/2002	US6468756 Methods of identifying compounds that bind to SNORF25 receptors
10/22/2002	US6468542 Germination activated Ganoderma lucidum spores and method for producing the same
10/22/2002	US6468519 Polyanhydrides with biologically active degradation products
10/22/2002	CA2118670C Pharmaceutical compositions in semisolid form and a device for administration thereof
10/22/2002	CA2073084C The use of sulphur-containing carboxylic acids to combat physiologically-induced excitatory disorders and diseases related thereto as well as allergic diseases and also the preparation of corresponding medicaments
10/17/2002	WO2002081703A2 Mitogenic oxygenase regulators
10/17/2002	WO2002081690A1 Novel protein, dna thereof and use of the same
10/17/2002	WO2002081684A2 Antisense calpain nucleotides and uses thereof
10/17/2002	WO2002081668A2 Desaturase genes and uses thereof
10/17/2002	WO2002081636A2 Protein modification and maintenance molecules
10/17/2002	WO2002081627A2 Methods of screening and using inhibitors of angiogenesis
10/17/2002	WO2002081520A2 Single chain dimeric polypeptides derived from the vegf family
10/17/2002	WO2002081508A2 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002	WO2002081499A2 Somatostatin agonists
10/17/2002	WO2002081475A1 Jun kinase inhibitors
10/17/2002	WO2002081471A1 Beta-carboline derivatives and its pharmaceutical use against depression and anxiety
10/17/2002	WO2002081467A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
10/17/2002	WO2002081464A1 Benzoaxathiepin derivatives and their use as medicines
10/17/2002	WO2002081463A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002	WO2002081461A1 Piperazine derivatives as tachykinin antagonists
10/17/2002	WO2002081460A1 Lipid lowering biphenylcarboxamides
10/17/2002	WO2002081453A1 Thiohydantoins and use thereof for treating diabetes
10/17/2002	WO2002081449A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/17/2002	WO2002081448A1 Benzamidine derivative
10/17/2002	WO2002081415A2 Method for inhibiting metap2
10/17/2002	WO2002080979A2 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	WO2002080976A2 Hsa-free formulations of interferon-beta
10/17/2002	WO2002080959A1 Method of treatment of hypoxia/ischaemia blutflusswiderstand
10/17/2002	WO2002080954A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
10/17/2002	WO2002080953A2 Method for reducing cellular damage resulting from hypoxia/ischaemia-related inflammation
10/17/2002	WO2002080952A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
10/17/2002	WO2002080943A1 Zinc ionophores as anti-stress agents
10/17/2002	WO2002080935A1 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
10/17/2002	WO2002080928A1 N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
10/17/2002	WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	WO2002080914A2 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002	WO2002080911A2 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases
10/17/2002	WO2002080910A1 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
10/17/2002	WO2002080900A1 Method for improving the well-being of poultry by in-ovo injection of carnitine
10/17/2002	WO2002080887A2 Timed pulse release composition
10/17/2002	WO2002080847A2 Use of tumor necrosis factor inhibitors to treat cardiovascular disease
10/17/2002	WO2002068414A3 Analogs of thalidomide as potential angiogenesis inhibitors
10/17/2002	WO2002062301A3 Method and composition for rejuvinating cells, tissues, organs, hair and nails
10/17/2002	WO2002049626A3 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity
10/17/2002	WO2002042292A3 Indol derivative and their use as inhibitors of p38 kinase
10/17/2002	WO2002040700A3 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
10/17/2002	WO2002038607A3 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
10/17/2002	WO2002036605A9 Estrone-derivatives having cytoprotective activity
10/17/2002	WO2002036108A3 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases
10/17/2002	WO2002034726A3 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/17/2002	WO2002029061A3 G-protein coupled receptors
10/17/2002	WO2002017891A3 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
10/17/2002	WO2002015920A3 Treatment of hyperproliferative diseases
10/17/2002	WO2002010192A9 Somatostatin analogues
10/17/2002	WO2002002148A3 Dual recombinant gene therapy compositions and methods of use
10/17/2002	WO2001098344A3 Angiogenesis-modulating compositions and uses
10/17/2002	WO2001098323A3 G-protein coupled receptors
10/17/2002	WO2001077378A3 Diagnosis of diseases associated with dna adducts
10/17/2002	WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002	WO2000000211A3 Hydrocolloids obtained from portulaca oleracea and the use thereof
10/17/2002	US20020152485 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
10/17/2002	US20020151723 Such as 1-(cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-((2'-(1H-tetrazol-t-yl)biphenyl-4-yl)methyl)benzimidazol-7-carboxylate; exhibits antihypertensive activity and strong angiotensin II antagonistic activity
10/17/2002	US20020151680 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
10/17/2002	US20020151596 Novel process to prepare 2-aminoindan derivatives
10/17/2002	US20020151594 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
10/17/2002	US20020151591 4-oxo-1,4-tetrahydro-1,5- naphthyridine-3-carboxamide derivative useful in treatment of disorders associated with cognition impairment including, Alzheimer's, vascular dementia, Parkinson's disease etc
10/17/2002	US20020151576 Inhibiting sodium/hydrogen exchanger activity and the n-type calcium channel with imidazoline derivatives
10/17/2002	US20020151574 Extracellular signal regulated kinase (ERK); anticancer agents and protein kinase inhibitors
10/17/2002	US20020151573 Anticancer agents
10/17/2002	US20020151569 Peroxisome Proliferator Activated Receptors (PPARs) antagonists 4-oxo-5-thiazolidine acetamide derivatives
10/17/2002	US20020151560 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
10/17/2002	US20020151558 Triazolo compounds as MMP inhibitors
10/17/2002	US20020151555 Pyrimidine matrix metalloproteinase inhibitors
10/17/2002	US20020151547 Substituted phenyl-piperidine methanone compounds
10/17/2002	US20020151536 Substituted azetidinone is used as sterol absorption inhibitor and a fibric acid derivative selected from fenofibrate, clofibrate, gemfibrozil, ciprofibrate, bezafibrate, clinofibrate etc
10/17/2002	US20020151530 Administering to a woman, undergoing estrogen replacement therapy for treating homonal deficiences, continuously and uninterruptedly, a therapeutic effective amount of both estrogen and a non-aromatizing androgen in daily dosage

1 ... 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 ... 1595